Table 1.

Patient characteristics

Patient 1Patient 2Patient 3Patient 4Patient 5
Age, year 14 15 
Specimen used for genotyping Muscle Muscle Muscle Muscle Muscle 
DNA changes c.1633G>A c.3140A>G c.1624G>A c.1624G>A c.1633G>A 
VAF (%)a 15 25 12 21 14 
Amino acid change p.Glu545Lys p.His1047Arg p.Glu542Lys p.Glu542Lys p.Glu545Lys 
COSMICb genomic mutation ID COSV55873239 COSV55873195 COSV55873227 COSV55873227 COSV55873239 
Treatments prior to alpelisib Botulinum toxin injections Botulinum toxin injections 
Patient 1Patient 2Patient 3Patient 4Patient 5
Age, year 14 15 
Specimen used for genotyping Muscle Muscle Muscle Muscle Muscle 
DNA changes c.1633G>A c.3140A>G c.1624G>A c.1624G>A c.1633G>A 
VAF (%)a 15 25 12 21 14 
Amino acid change p.Glu545Lys p.His1047Arg p.Glu542Lys p.Glu542Lys p.Glu545Lys 
COSMICb genomic mutation ID COSV55873239 COSV55873195 COSV55873227 COSV55873227 COSV55873239 
Treatments prior to alpelisib Botulinum toxin injections Botulinum toxin injections 
a

Corresponds to the percentage of alternate or mutant reads to total reads detected by next-generation sequencing.

b

Catalogue of Somatic Mutations in Cancer.

or Create an Account

Close Modal
Close Modal